Sopharma AD-Sofia (WAR:SPH) EPS without NRI: zł0.86 (TTM As of Mar. 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
67 GF Score
Price zł7.50
GF Value zł13.45
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia EPS without NRI?

Sopharma AD-Sofia WAR:SPH -3.60% 67 EPS without NRI is zł0.86 as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 101 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 990098.02% on this metric.

Sopharma AD-Sofia's earnings per share without non-recurring items for the three months ended in Mar. 2026 was zł0.27. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.86.

During the past 12 months, Sopharma AD-Sofia's average earnings per share (NRI) Growth Rate was 61.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Sopharma AD-Sofia's EPS without NRI or its related term are showing as below:

During the past 13 years, Sopharma AD-Sofia's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 41.10% per year. The lowest was -19.20% per year. And the median was -3.00% per year.

WAR:SPH's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 2.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Sopharma AD-Sofia's EPS (Diluted) for the three months ended in Mar. 2026 was zł0.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.91.

Sopharma AD-Sofia's EPS (Basic) for the three months ended in Mar. 2026 was zł0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.93.


Sopharma AD-Sofia  (WAR:SPH) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sopharma AD-Sofia EPS without NRI Related Terms


Sopharma AD-Sofia EPS without NRI Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia EPS without NRI Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.24 1.33 1.43 0.90 -0.01

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.33 0.17 0.10 0.27

WAR:SPH vs MCK, CAH, COR: EPS without NRI Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia PE Ratio without NRI vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's PE Ratio without NRI falls into.


WAR:SPH
67GF Score
Sopharma AD-Sofia WAR:SPH
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of zł0.86 mean?
Sopharma AD-Sofia (WAR:SPH) has a EPS without NRI of zł0.86 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies in the Medical Distribution industry.
Is Sopharma AD-Sofia's EPS without NRI too high?
Sopharma AD-Sofia's current EPS without NRI is zł0.86. Based on the distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EPS without NRI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 101 companies for EPS without NRI. This places Sopharma AD-Sofia in the lower half of its industry. The industry median EPS without NRI is 2.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Distribution company?
The median EPS without NRI among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median EPS without NRI is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current EPS without NRI is zł0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.45, compared to a current price of zł7.50 — trading 44.2% below its estimated fair value. The current EPS without NRI is zł0.86. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EPS without NRI is zł0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.50 is trading 44.2% below its estimated GF Value™ of zł13.45. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • EPS without NRI: zł0.86
  • GF Value™: zł13.45 vs. price of zł7.50 (44.2% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score

Get the complete analysis for WAR:SPH

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.50
Price
zł13.45
GF Value